Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|1|60-70

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.1, 2018-01, pp. : 60-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 820-823

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 41-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 179-186

John Wiley & Sons Inc

Access to resources Recommend Favorite